Last update 20 Mar 2025

Palupiprant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [1]
Target
Action
antagonists
Mechanism
EP4 antagonists(Prostanoid EP4 receptor antagonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18F5N3O4
InChIKeyMKLKAQMPKHNQPR-NSHDSACASA-N
CAS Registry1369489-71-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Rectal CarcinomaPhase 2
United Kingdom
22 May 2024
Advanced cancerPhase 2
United States
30 Jul 2015
Advanced cancerPhase 2
France
30 Jul 2015
Triple Negative Breast CancerPhase 1
France
20 Aug 2020
Triple Negative Breast CancerPhase 1
United States
20 Aug 2020
Uterine Cervical CancerPhase 1
United States
20 Aug 2020
Uterine Cervical CancerPhase 1
France
20 Aug 2020
Rectal CancerPhase 1
United Kingdom
17 May 2017
Rectal CancerPhase 1
Poland
17 May 2017
Rectal CancerPhase 1
United States
17 May 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
AN0025 250 mg
(xuhvzgoeaq) = xfrbttbjzn lpxzrqkixj (xnibudiuwq )
Positive
16 Sep 2024
Phase 1
12
(jtqxuhhltx) = bsoigcqjhs sbgpvvnzag (zcoomptplp )
Positive
24 May 2024
Phase 1
-
(gbcbbyfifv) = ldopgztxkz jdyxphuprk (rjwajctemy )
-
16 Sep 2021
Phase 1
30
(kxbdjrxalj) = ghkldfjrje jbvivrbtgy (ujscjickrh )
Positive
01 Jun 2020
Phase 1
31
(E7046 125 mg)
(ymgqrkqzhs) = zqyhlpurfl soymgtgwjv (suezodimoz, kmbwvxpdak - nlrfjbnrki)
-
17 Feb 2020
(E7046 250 mg)
(ymgqrkqzhs) = lkfcbfdhcq soymgtgwjv (suezodimoz, gedktgqlbt - ipswimsxwk)
Phase 1
27
chemoradiotherapy+Palupiprant
(250 mg cohort)
(uhgzbzueae) = No DLT was observed among 13 evaluable pts in this dose level. mopeoircct (elbgkiczyb )
Positive
29 Sep 2019
chemoradiotherapy+Palupiprant
Phase 1
Advanced Malignant Solid Neoplasm
CD3 + | CD8 + | CXCL10 ...
30
zvulvqyihy(zpiharlato) = 3 patients, at 250 mg, 750 mg lurgztpelw (qgrqipcdin )
Positive
07 Dec 2017
Phase 1
-
ayztimqwbh(uqrzudbgwt) = qhulftxerf wxtvbxfyxo (deygrtrepv )
Positive
01 Oct 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free